Harmony Biosciences Appoints New COO and Board Members

By Chris Stiles • Thursday, April 02 10:14 • Permanent Link

Harmony Biosciences reshaped its leadership on April 2, 2026, appointing Peter Anastasiou as chief operating officer, adding Troy Ignelzi to its board, and nominating Geno J. Germano for election at the 2026 annual meeting.

Anastasiou joins the executive team after serving on Harmony’s board. He most recently was chief executive officer of Capsida Biotherapeutics and previously held senior roles at Lundbeck, including president of U.S. and Canadian operations and U.S. chief commercial officer for psychiatry and neurology. His move to COO means he will now oversee operational execution across the company. With that appointment, he resigned from the board.

Ignelzi steps into the board seat left open by Anastasiou’s resignation and will serve the remainder of that term before standing for re-election in 2026. He is currently chief financial officer of Rapport Therapeutics and previously was CFO of Karuna Therapeutics, where he helped lead a private crossover round, the company’s IPO, and multiple follow-on financings. Harmony highlighted his background in capital formation, strategic transactions, and governance.

At the same time, Antonio Gracias said he will not stand for re-election at the 2026 annual meeting. Gracias has served on the board since September 2017 and chairs the compensation committee.

Harmony’s board also nominated Germano for election at the 2026 annual meeting, pending shareholder approval. Germano brings 35 years in pharmaceuticals and life sciences. He most recently served as president and CEO of Elucida Oncology and earlier was president of Intrexon. His prior roles include senior leadership positions at Pfizer, Johnson & Johnson, and Wyeth, including group president of Pfizer’s global innovative pharmaceutical business and president and general manager of its specialty care, vaccines, and oncology units. He also chaired Sage Therapeutics until its acquisition by Supernus Pharmaceuticals in July 2025.

The company said the changes are aimed at supporting its next phase of growth and long-term value creation. Today the company's shares have moved -0.54% to a price of $27.44. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.